Literature DB >> 760753

Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs.

E Perucca, A Richens.   

Abstract

1 The serum concentration profile of paracetamol has been determined after administration of single 1000 mg intravenous and oral doses in six normal subjects and six epileptic patients on chronic antiepileptic drug therapy. The urinary excretion of free and conjugated paracetamol has also been determined. 2 Following intravenous administration, serum paracetamol concentration declined with first-order kinetics. Both elimination rate and total body clearance were higher in the epileptic patients, although in neither case was the difference statistically significant. 3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups. 4 It is suggested that the lower bioavailability of paracetamol in the epileptic patients results from enhancement of first-pass metabolism, secondary to enzyme induction.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760753      PMCID: PMC1429435          DOI: 10.1111/j.1365-2125.1979.tb00922.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Temporal variations in acetaminophen and phenacetin half-life in man.

Authors:  C A Shively; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Hepatic enzyme induction and its relationship to urinary D-glucaric acid excretion in man.

Authors:  D S Lecamwasam
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

3.  Pharmacokinetics in the elderly.

Authors:  E J Triggs; R L Nation; A Long; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

4.  Effect of pentobarbital on the disposition of alprenolol.

Authors:  G Alván; K Piafsky; M Lind; C von Bahr
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

5.  Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat.

Authors:  A S Nies; G R Wilkinson; B D Rush; J R Strother; D G McDevitt
Journal:  Biochem Pharmacol       Date:  1976-09-01       Impact factor: 5.858

6.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

7.  Drugs and the liver. I. Effects of glutethimide and phenobarbital on hepatic bilirubin clearance, plasma bilirubin turnover and carbon monoxide production in man.

Authors:  T F Blaschke; P D Berk; F L Rodkey; B F Scharschmidt; H A Collison; J G Waggoner
Journal:  Biochem Pharmacol       Date:  1974-10-15       Impact factor: 5.858

8.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

9.  Drug therapy. Acetaminophen.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1976-12-02       Impact factor: 91.245

10.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.

Authors:  M D Rawlins; D B Henderson; A R Hijab
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

View more
  32 in total

Review 1.  [Polypharmacy and pain treatment].

Authors:  Markus Gosch; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Bernhard Iglseder; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 2.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

Review 5.  Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation.

Authors:  Scott M Suchin; David C Wolf; Young Lee; Gita Ramaswamy; Patricia A Sheiner; Marcelo Facciuto; Michael R Marvin; Leona Kim-Schluger; Edward Lebovics
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

6.  Effect of febrile illness and its treatment on anticonvulsant levels in children.

Authors:  K J Goulden
Journal:  CMAJ       Date:  1986-06-15       Impact factor: 8.262

7.  The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man.

Authors:  J A Clements; J A Critchley; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

Review 8.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

9.  Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking.

Authors:  K W Bock; J Wiltfang; R Blume; D Ullrich; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.

Authors:  Angela Villiger; Cordula Stillhart; Neil Parrott; Martin Kuentz
Journal:  AAPS J       Date:  2016-04-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.